Evaluation of the Survival Rate and Clinical Outcome of Nanodrug Administration for the Treatment of Lung Cancer: A Systematic Review and Meta-analysis

Document Type : Review Article


1 Department of Pathology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

2 Department of Internal Medicine, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran

3 Department of Internal Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

4 Chronic Respiratory Diseases Research Center (CRDRC), Shahid Beheshti University of Medical Sciences, Tehran, Iran

5 Department of Internal Medicine, Noor Iranian Polyclinic, Muscat, Oman


Background and aim: During the last two decades, with the introduction of nanotechnology, a more promising perspective for cancer treatment appeared, and many research was conducted in nanomedicine. Based on the findings of studies, nanoparticles improve bioavailability, overcome biophysical and biochemical barriers, and reduce cytotoxicity. This study aims to evaluate the survival rate and clinical outcome of nanodrug administration for lung cancer treatment.
Material and methods: In this study, international databases such as PubMed, Scopus, Science Direct, ISI, Web of Knowledge, and Embase were reviewed to select articles related to the purpose of this study from January 2012 to July 2022. Effect size with 95% confidence interval (CI) with fixed effect modal and inverse-variance done. STATA.V16 software was used for data analysis.
Results:  In the initial review, the abstracts of 183 studies were reviewed, two authors reviewed the full text of 34 studies, and finally, seven studies were selected. Overall survival rate and Progression-Free survival rate between nab-paclitaxel plus carboplatin compared solvent-based paclitaxel plus cisplatin in lung cancer patients was 88% (HR: 95% CI, 0.51 to 1.25; p=0.00) and 77% (HR: 95% CI, 0.37 to 1.17; p=0.00), respectively.
Conclusions: Based on the findings of the present meta-analysis, nab-paclitaxel administration can prolong the progression-free survival rate; improve the objective response rate, and increase the overall survival rate.


Main Subjects

[1]  Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021;71(3):209-49. https://doi.org/10.3322/caac.21660.
[2]  Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JH, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. Journal of thoracic oncology. 2015;10(9):1243-60. https://doi.org/10.1097/JTO.0000000000000630.
[3]  Esagian SM, Grigoriadou GΙ, Nikas IP, Boikou V, Sadow PM, Won JK, et al. Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: A comprehensive systematic review. Journal of cancer research and clinical oncology. 2020;146(8):2051-66. https://doi.org/10.1007/s00432-020-03267-x.
[4.] Planchard D, Besse B, Groen HJ, Hashemi SM, Mazieres J, Kim TM, et al. Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis. Journal of Thoracic Oncology. 2022;17(1):103-15. https://doi.org/10.1016/j.jtho.2021.08.011.
[5]  Freitas LF, Ferreira AH, Thipe VC, Varca GH, Lima CS, Batista JG, et al. The State of the Art of Theranostic Nanomaterials for Lung, Breast, and Prostate Cancers. Nanomaterials. 2021;11(10):2579. https://doi.org/10.3390/nano11102579.
[6]  Ahmad A, Gadgeel SM, editors. Lung cancer and personalized medicine: Novel therapies and clinical management. Cham: Springer; 2016.
[7]  Lemjabbar-Alaoui H, Hassan OU, Yang YW, Buchanan P. Lung cancer: Biology and treatment options. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2015;1856(2):189-210. https://doi.org/10.1016/j.bbcan.2015.08.002.
[8]  Taylor SA, Mallett S, Ball S, Beare S, Bhatnagar G, Bhowmik A, et al. Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial. The Lancet Respiratory Medicine. 2019;7(6):523-32. https://doi.org/10.1016/S2213-2600(19)30090-6.
[9]  Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nature Reviews Disease Primers. 2021;7(1):1-20. https://doi.org/10.1038/s41572-020-00235-0.
[10] Ferrara MG, Di Noia V, D’argento E, Vita E, Damiano P, Cannella A, et al. Oncogene-addicted non-small-cell lung cancer: Treatment opportunities and future perspectives. Cancers. 2020;12(5):1196. http://dx.doi.org/10.3390/cancers12051196.
[11] Kocher F, Hilbe W, Seeber A, Pircher A, Schmid T, Greil R, et al. Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry. Lung Cancer. 2015;87(2):193-200. https://doi.org/10.1016/j.lungcan.2014.12.006.
[12] Kawai H, Saito Y. Combination of Juzentaihoto and chemotherapy improves the prognosis of patients with postoperative recurrence of non‑small cell lung cancer. Molecular and Clinical Oncology. 2020;13(3):1-. https://doi.org/10.3892/mco.2020.2083.
[13] Yano T, Okamoto T, Fukuyama S, Maehara Y. Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer. World Journal of Clinical Oncology. 2014;5(5):1048-54. https://doi.org/10.5306%2Fwjco.v5.i5.1048.
[14] Jiang H, Xu A, Xia W, Xia X, Li P, Zhang B, et al. Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis. Cancer cell international. 2021;21(1):1-2. https://doi.org/10.1186/s12935-021-02100-w.
[15] Cortellini A, Bersanelli M, Santini D, Buti S, Tiseo M, Cannita K, et al. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. European Journal of Cancer. 2020;128:17-26. https://doi.org/10.1016/j.ejca.2019.12.031.
[16] Xia L, Liu Y, Wang Y. PD‐1/PD‐L1 blockade therapy in advanced non‐small‐cell lung cancer: current status and future directions. The oncologist. 2019;24(S1):S31-41. https://doi.org/10.1634/theoncologist.2019-IO-S1-s05.
[17] Liu Y, Zhou S, Du Y, Sun L, Jiang H, Zhang B, et al. Efficacy and safety of programmed death 1 inhibitors in patients with advanced non-small cell lung cancer: a meta-analysis. Cancer Management and Research. 2019;11:4619-30. https://doi.org/10.2147%2FCMAR.S193394.
[18] Zhang B, Liu Y, Zhou S, Jiang H, Zhu K, Wang R. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis. International Immunopharmacology. 2020;80:106214. https://doi.org/10.1016/j.intimp.2020.106214.
[19] Park YI, Kwon SH, Lee G, Motoyama K, Kim MW, Lin M, et al. pH-sensitive multi-drug liposomes targeting folate receptor β for efficient treatment of non-small cell lung cancer. Journal of Controlled Release. 2021;330:1-14. https://doi.org/10.1016/j.jconrel.2020.12.011.
[20] Bayón-Cordero L, Alkorta I, Arana L. Application of solid lipid nanoparticles to improve the efficiency of anticancer drugs. Nanomaterials. 2019;9(3):474. https://doi.org/10.3390/nano9030474.
[21] Khiev D, Mohamed ZA, Vichare R, Paulson R, Bhatia S, Mohapatra S, et al. Emerging nano-formulations and nanomedicines applications for ocular drug delivery. Nanomaterials. 2021;11(1):173. https://doi.org/10.3390/nano11010173.
[22] Li S, Xu S, Liang X, Xue Y, Mei J, Ma Y, et al. Nanotechnology: breaking the current treatment limits of lung cancer. Advanced Healthcare Materials. 2021;10(12):2100078. https://doi.org/10.1002/adhm.202100078.
[23] Weiss JM, Pennell N, Deal AM, Morgensztern D, Bradford DS, Crane J, et al. Nab‐paclitaxel in older patients with non–small cell lung cancer who have developed disease progression after platinum‐based doublet chemotherapy. Cancer. 2020;126(5):1060-7. https://doi.org/10.1002/cncr.32573.
[24] Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. Journal of the Chinese medical association. 2020;83(3):217-20. https://doi.org/10.1097%2FJCMA.0000000000000270.
[25] Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. Bmj. 2011;343. https://doi.org/10.1136/bmj.d5928.
[26] Lu J, Gu A, Wang W, Huang A, Han B, Zhong H. Polymeric micellar paclitaxel (pm-Pac) prolonged overall survival for NSCLC patients without pleural metastasis. International Journal of Pharmaceutics. 2022;623:121961. https://doi.org/10.1016/j.ijpharm.2022.121961.
[27] Shi M, Gu A, Tu H, Huang C, Wang H, Yu Z, et al. Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial. Annals of Oncology. 2021;32(1):85-96. https://doi.org/10.1016/j.annonc.2020.10.479.
[28] Hirsh V, Ko A, Pilot R, Renschler MF, Socinski MA. Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non–small-cell lung cancer: analysis of safety and efficacy in patients with diabetes. Clinical Lung Cancer. 2016;17(5):367-74. https://doi.org/10.1016/j.cllc.2016.04.002.
[29] Langer CJ, Hirsh V, Ko A, Renschler MF, Socinski MA. Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non–small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment. Clinical lung cancer. 2015;16(2):112-20. https://doi.org/10.1016/j.cllc.2014.09.003.
[30] Socinski MA, Okamoto I, Hon JK, Hirsh V, Dakhil SR, Page RD, et al. Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer. Annals of oncology. 2013;24(9):2390-6. https://doi.org/10.1093/annonc/mdt235.
[31] Satouchi M, Okamoto I, Sakai H, Yamamoto N, Ichinose Y, Ohmatsu H, et al. Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2013;81(1):97-101. https://doi.org/10.1016/j.lungcan.2013.02.020.
[32] Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012;30(17):2055-62. https://doi.org/10.1200/JCO.2011.40.1315.
[33] Bade BC, Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. Clinics in chest medicine. 2020;41(1):1-24. https://doi.org/10.1016/j.ccm.2019.10.001.
[34] Tang S, Qin C, Hu H, Liu T, He Y, Guo H, et al. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. Cells. 2022;11(3):320. https://doi.org/10.3390/cells11030320.
[35] Huang L, Zhao S, Fang F, Xu T, Lan M, Zhang J. Advances and perspectives in carrier-free nanodrugs for cancer chemo-monotherapy and combination therapy. Biomaterials. 2021;268:120557. https://doi.org/10.1016/j.biomaterials.2020.120557.
[36] Zhang Y, Huang Y, Li S. Polymeric micelles: nanocarriers for cancer-targeted drug delivery. Aaps Pharmscitech. 2014;15(4):862-71. https://doi.org/10.1208/s12249-014-0113-z.
[37] Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Annals of oncology. 2020;31(8):1056-64. https://doi.org/10.1016/j.annonc.2020.04.478.
[38] Jin C, Wang K, Oppong-Gyebi A, Hu J. Application of nanotechnology in cancer diagnosis and therapy-a mini-review. International Journal of Medical Sciences. 2020;17(18):2964-73. https://doi.org/10.7150%2Fijms.49801.
[39] Bernabeu E, Cagel M, Lagomarsino E, Moretton M, Chiappetta DA. Paclitaxel: what has been done and the challenges remain ahead. International journal of pharmaceutics. 2017;526(1-2):474-95. https://doi.org/10.1016/j.ijpharm.2017.05.016.
[40] Bavli Y, Winkler I, Chen BM, Roffler S, Cohen R, Szebeni J, et al. Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs. Journal of Controlled Release. 2019;306:138-48. https://doi.org/10.1016/j.jconrel.2019.06.007.
[41] Yuan Y, Cai T, Xia X, Zhang R, Chiba P, Cai Y. Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer. Drug delivery. 2016;23(9):3350-7. https://doi.org/10.1080/10717544.2016.1178825.
[42] Rihawi K, Gelsomino F, Sperandi F, Melotti B, Fiorentino M, Casolari L, et al. Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence. Therapeutic advances in respiratory disease. 2017;11(9):353-73. https://doi.org/10.1177%2F1753465817725486.
Volume 4, Issue 3
September 2022
Pages 140-147
  • Receive Date: 27 June 2022
  • Revise Date: 17 August 2022
  • Accept Date: 27 August 2022
  • First Publish Date: 01 September 2022